Literature DB >> 15059127

False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods.

F W Goldstein1, R Atoui, A Ben Ali, J C Nguyen, A Ly, M D Kitzis.   

Abstract

The combination of vancomycin and beta-lactams is often considered synergistic and has been recommended for the treatment of glycopeptide-intermediate Staphylococcus aureus (GISA) infections. In this study, the combination of vancomycin or teicoplanin with different beta-lactams was tested. When using NaCl 4% w/v, for better expression of heterogeneous resistance to beta-lactams, with a longer (48-h) incubation period and a higher (10(7) CFU/mL) inoculum, the association of vancomycin with beta-lactams was antagonistic. However, a synergistic effect was observed for teicoplanin under the same conditions.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15059127     DOI： 10.1111/j.1198-743X.2004.00856.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  8 in total

1.  In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

2.  Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty.

Authors:  Eduard Tornero; Sebastian García-Ramiro; Juan C Martínez-Pastor; Guillem Bori; Jordi Bosch; Laura Morata; Marta Sala; Misericordia Basora; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

3.  In Vitro Activity of Peptide Antibiotics in Combination With Other Antimicrobials on Extensively Drug-Resistant Acinetobacter baumannii in the Planktonic and Biofilm Cell.

Authors:  Qianlin Meng; Fei Lin; Baodong Ling
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

4.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

5.  Interactions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticus.

Authors:  Carla Vignaroli; Francesca Biavasco; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.

Authors:  S Ribes; M E Pachón-Ibáñez; M A Domínguez; R Fernández; F Tubau; J Ariza; F Gudiol; C Cabellos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-01       Impact factor: 3.267

7.  The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus.

Authors:  Michael Hort; Ute Bertsche; Senada Nozinovic; Alina Dietrich; Anne Sophie Schrötter; Laura Mildenberger; Katharina Axtmann; Anne Berscheid; Gabriele Bierbaum
Journal:  Microbiol Spectr       Date:  2021-10-20

8.  Ten-year decrease of acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at a single institution: the result of a multifaceted program combining cross-transmission prevention and antimicrobial stewardship.

Authors:  Annie Chalfine; Marie-Dominique Kitzis; Yvonnick Bezie; Adel Benali; Laurence Perniceni; Jean-Claude Nguyen; Marie Françoise Dumay; Jacqueline Gonot; Gilles Rejasse; Fred Goldstein; Jean Carlet; Benoît Misset
Journal:  Antimicrob Resist Infect Control       Date:  2012-05-18       Impact factor: 4.887
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.